COVID-19: risk for cytokine targeting in chronic inflammatory diseases? #MMPMID32296135
Schett G; Sticherling M; Neurath MF
Nat Rev Immunol 2020[May]; 20 (5): 271-272 PMID32296135show ga
COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising infection rates, patient groups characterized by an enhanced infection risk will be challenged by the virus. In this context, patients with chronic immune-mediated inflammatory diseases are of particular interest, as these diseases are characterized by an intrinsic immune dysfunction leading to inflammation that may enhance risk for severe infection.